Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Insulet (PODD) being highlighted as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Earnings Growth - Insulet has a historical EPS growth rate of 161.2%, with projected EPS growth of 50.8% for the current year, significantly outperforming the industry average of 12.2% [5][4]. Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 17.4%, which is substantially higher than the industry average of 2.6%. Over the past 3-5 years, Insulet's annualized cash flow growth rate has been 51.1%, compared to the industry average of 8.2% [6][7]. Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Insulet, with the Zacks Consensus Estimate for the current year increasing by 6% over the past month, indicating strong near-term stock price movement potential [8][10]. Overall Positioning - Insulet holds a Zacks Rank of 2 (Buy) and a Growth Score of A, positioning it well for potential outperformance in the growth stock category [10].

Core Viewpoint - Abbott Laboratories has initiated a recall in the United States for specific FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors due to internal testing revealing certain issues [1] Group 1 - The recall affects certain models of the FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors [1] - Internal testing conducted by the company indicated that some sensors may not perform as expected [1] - The company is taking corrective actions to address the identified issues with the sensors [1]

Group 1 - Dividend stocks are a slow and steady investment strategy that can provide significant rewards over time through compounding [1][2] - Investors should look for established companies with a history of growth and consistent dividend increases [2] - Five blue-chip dividend stocks are highlighted as strong investment options for the current month [2] Group 2 - Chevron is a major player in the oil and gas industry, with a 37-year history of annual dividend increases [4] - The company expects to grow its free cash flow by at least 10% annually through 2030 if oil prices average $70 per barrel, supporting future dividend hikes [5] - Chevron currently offers a dividend yield of 4.4% [5] Group 3 - Medtronic is a leading global medical device company with a 47-year history of raising dividends [6][7] - The company operates in three segments: cardiovascular, surgical, and neuroscience, and is focused on innovation to meet growing healthcare needs [6] - Medtronic's stock offers a 2.8% dividend yield and is currently trading at a price-to-earnings ratio of under 18 [7]

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Okami Medical has raised $45 million to commercialize medical devices for stopping blood flow, the company said last week.  The company has developed technology that it claims could make vascular embolization faster and better. It competes with embolization coils such as Boston Scientific’s Interlock and Terumo’s Azur. Okami named Drew Hykes as CEO i ...

Core Viewpoint - Ademi & Fruchter LLP is investigating potential securities fraud claims against DexCom, Inc. due to inaccurate statements regarding its business operations and the quality of its products [1][2]. Group 1: Investigation Details - The investigation centers on DexCom's claims about its G7 blood glucose monitor, asserting it was of high quality and manufactured with FDA-approved materials [2]. - Reports indicate that DexCom altered the sensor membrane coating material from a third-party supplier to an in-house formulation without notifying the FDA or investors, which deviated from the FDA-approved formulation [2]. - The investigation period spans from January 8, 2024, to September 17, 2025 [2].

NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Accessibility StatementSkip Navigation Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inspire-medical-systems-inc-loss-su ...

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [1][2]. Summary by Sections Allegations - The lawsuit claims that Baxter's Novum LVP product had systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects [1]. - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted [1]. - There was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [1]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [1]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [1]. - Shareholders who purchased shares during this period are encouraged to register for participation in the class action, with a deadline for lead plaintiff appointment set for December 15, 2025 [2]. Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3].

Accessibility StatementSkip Navigation Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected] Phone: (646) 453-8903 NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders ...

Core Insights - GE HealthCare has submitted a 510(k) application to the U.S. FDA for its new photon-counting computed tomography (PCCT) system, Photonova Spectra, which incorporates advanced AI algorithms [1] - This submission represents a significant milestone in GE HealthCare's long history of innovation in computed tomography [1] - Photonova Spectra utilizes GE HealthCare's proprietary Deep Silicon detector technology, aiming to provide exceptional spectral and spatial resolution for ultra-high-definition imaging [1]

Core Viewpoint - Inspire Medical Systems, Inc. is recognized for its innovative sleep apnea treatment solutions, particularly the Inspire therapy device, while facing a class action lawsuit that may impact investor sentiment [1][2][5] Company Overview - Inspire Medical Systems specializes in medical solutions for sleep apnea, particularly through its implantable Inspire therapy device [1] - The company's current stock price is $89.87, reflecting a recent increase of 7.92% or $6.60 [3][5] - The market capitalization of Inspire Medical Systems is approximately $2.66 billion, indicating its significant presence in the market [3] Analyst Ratings - Stifel Nicolaus has upgraded Inspire Medical Systems to a "Buy" rating with a price target of $110, suggesting a potential increase of 22.4% from the current stock price [1][5] Legal Challenges - The company is currently involved in a class action lawsuit led by the Schall Law Firm, alleging violations of the Securities Exchange Act of 1934, affecting investors who purchased INSP securities between August 6, 2024, and August 4, 2025 [2][5] - Shareholders who have experienced losses are encouraged to contact the law firm before January 5, 2026 [2] Trading Activity - The trading volume for INSP on the NYSE is 1,073,158 shares, indicating active investor interest despite ongoing legal challenges [4][5] - The stock has fluctuated between $83.37 and $90.55 today, with a yearly high of $216.01 and a low of $70.77 [3]